Drugs / PD-1 knockout
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03525782 | Feb 2018 → Jan 2021 | non-small cell lung carcinoma | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 knockout | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525782 ↗ |
| Action | Inhibit | “PD-1 knockout Engineered T cells” NCT03525782 ↗ |
| Modality | Cell therapy | “PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.” NCT03525782 ↗ |
| Target | PDCD1 | “PD-1 knockout Engineered T cells” NCT03525782 ↗ |